pharmacovigilance

Pharmacovigilance is the ongoing safety watch kept over a drug throughout its life on the market. Approval is granted on the evidence of trials in a few thousand people, but the true safety story only unfolds once millions take the drug in everyday conditions. Pharmacovigilance is the system that keeps listening, gathering reports of harm long after the launch party is over.

Its core activity is detecting, assessing, understanding, and preventing adverse effects. Doctors, pharmacists, patients, and companies report suspected reactions into spontaneous reporting databases; specialists then sift this flood of reports for patterns, or signals, that a drug might be causing a problem not seen in trials. Suspected signals are investigated further, sometimes with dedicated studies, to judge whether the link is real.

When a genuine hazard is confirmed, pharmacovigilance feeds action. Regulators may update the label with new warnings, restrict the approved uses, require risk-management measures, or, for a serious enough problem, withdraw the drug. The discipline thus closes the loop on a drug's risk-benefit balance, which is never settled once and for all but re-judged as evidence accumulates.

The system has real limits. Spontaneous reporting is voluntary and incomplete, so many reactions go unreported, and a report only shows a suspected, not proven, link. Because the true number of people exposed is rarely known, raw counts cannot give a reliable rate, so signals usually need confirmation by more rigorous study before firm conclusions are drawn.